GU Cancers 2020 | KEYNOTE-365: pembrolizumab combination therapy for mCRPC

William Berry

William Berry, MD, Duke University Medical Center, Durham, NC, discusses the KEYNOTE-365 trial (NCT02861573) which investigated pembrolizumab combinations for the treatment of metastatic castrate-resistant prostate cancer (mCRPC). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter